Merck, BMS Prepare To Seek FDA Reversal On OTC Cholesterol Drugs

Merck and Bristol-Myers Squibb are aiming to switch the lowest dosage levels of their respective Rx cholesterol-lowering drugs, Mevacor (lovastatin) and Pravachol (pravastatin), to OTC status. The firms have filed NDAs for approval of OTC 10 mg daily doses.